An interventional study of miRNA typing in Osteoporosis and Menopause, sponsored by Istituto Auxologico Italiano. Recruiting at 2 sites in Italy. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Istituto Auxologico Italiano · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Osteoporosis with a site in Italy — 21 open to participants now, 25 under way, none of them phase 3. Osteoporosis · Italy.
Among the 60 studies in Osteoporosis with a site in Italy, this one is the 30th largest by planned enrollment of the 35 interventional ones that give a count, is one of 6 that started in 2025, is one of 16 with no phase, reaches primary completion later than 23 of the 24 other live ones, and was the 60th registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →21 of the 60 studies in Osteoporosis with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 30–45 · Women only · Healthy volunteers
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 5–18
Regina Elena Cancer Institute · Sites in Italy
Ages 35–70 · Women only
IRCCS San Raffaele · Sites in Italy
Ages 50+ · Men only
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 40+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 15 · Phase 4 3
First in 2001; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 120 across the 35 interventional studies, 150 across the 25 observational. Of the 31 that completed or were terminated, 11 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 60 have an industry lead sponsor. The 10 most frequent:
Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.
Istituto Auxologico Italiano has 6 studies filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Osteoporosis with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06551155Istituto Ortopedico RizzoliPeripheral Mononuclear Cells to Screen, Monitor and Stratify the Population at Risk of Osteoporosis and Fractures | 2026-12-21 |
| NCT07508553Fondazione Policlinico Universitario Agostino Gemelli IRCCSComparison of Bone Mineral Density in the Third Trimester Between Women in Singleton and Twin Pregnancies Using Questionnaires and REMS Densitometric Examination | 2026-12-23 |
| NCT04730622Istituto Ortopedico RizzoliStudy of Parameters of Osteosarcopenia in Patients With Hip Fracture | 2026-12-31 |
| NCT07512453Azienda Ospedaliero, Universitaria PisanaStudy in Patients With Osteoporosis and Fragility Fractures to Estimate the Extent and Impact of Delayed Administration of Anti-fracture Therapy | 2027-03-31 |
| NCT04796350AgNovos Healthcare, LLCRESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | 2027-04-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 60 studies in Osteoporosis with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Osteoporosis is a systemic skeletal disorder affecting approximately 10% of individuals over 50 years of age. It is characterised by an increased risk of fragility fractures, which constitute a major source of morbidity, mortality, and healthcare burden worldwide.
A range of pharmacological therapies has been approved for osteoporosis, with demonstrated efficacy in reducing fracture risk. These include anabolic agents that stimulate osteoblast-mediated bone formation (teriparatide, abaloparatide), antiresorptive agents that inhibit osteoclast-driven bone resorption (bisphosphonates, denosumab), and dual-action agents such as romosozumab, which, through sclerostin inhibition, simultaneously enhances bone formation and suppresses resorption. In clinical practice, these agents are administered sequentially or in combination to optimise therapeutic outcomes.
The primary goal of anti-osteoporotic therapy is to reduce the risk of incident and subsequent fractures. In postmenopausal osteoporosis, this objective is closely linked to meaningful gains in bone mineral density (BMD), as measured by dual-energy X-ray absorptiometry (DEXA), with attainment of osteopenic ranges associated with low fracture probability (\<15% for major osteoporotic fractures and \<3% for hip fractures, according to FRAX). However, selecting the most effective therapeutic strategy remains challenging, as robust predictors of individual treatment response are lacking. Although bone turnover markers are widely used to monitor treatment effects, their value in predicting clinical outcomes is limited.
MicroRNAs (miRNAs) are small (\~22 nucleotides), single-stranded, non-coding RNAs that regulate gene expression at the post-transcriptional level through binding to complementary sequences in target mRNAs. Circulating miRNAs are stabilised by association with proteins and extracellular vesicles, making them attractive candidates as biomarkers. Increasing evidence indicates that miRNAs play key roles in osteoblast and osteoclast differentiation, proliferation, and apoptosis, and distinct miRNA expression profiles have been associated with osteoporosis and fragility fractures.
An emerging area of interest is the interaction between osteoactive therapies and circulating miRNA signatures. To date, available data are largely limited to antiresorptive agents and teriparatide. No studies have yet addressed miRNA expression profiles in patients treated with romosozumab or abaloparatide.
Beyond miRNAs, additional molecular pathways implicated in osteoimmunological crosstalk and ageing are gaining attention as potential biomarkers. Nitric oxide (NO) plays a multifaceted role in bone homeostasis, inhibiting osteoclast activity while promoting osteoblast function. Reduced circulating NO levels have been identified as an independent predictor of osteoporotic fractures in postmenopausal women. Autophagy is increasingly recognised as a critical regulator of bone remodelling, influencing both osteoblastic and osteoclastic activity. Dysregulation of autophagic pathways disrupts bone homeostasis and contributes to bone loss. These processes are tightly controlled by complex molecular networks, including miRNAs, and are closely linked to lysosomal function. In this context, cathepsin K has emerged as a promising therapeutic target in osteoporosis.
The present study primarily aims to identify circulating microRNAs, whose early treatment-induced changes are predictive of the outcome of the therapy in terms of changes in BMD. Secondary, it aims to identify correlations of the changes in microRNAs serum concentrations with variations in biomarkers of bone metabolism as well as of aging.
The study enrols women with diagnosis of severe postmenopausal osteoporosis addressed to treatment with romosozumab or with abaloparatide. All women will be assessed at baseline and after 2, 6 and 12 months of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal women treated with romosozumab for twelve months
Diagnostic Test: miRNA typing
Postmenopausal women treated with abaloparatide for twelve months
Diagnostic Test: miRNA typing
Identification circulating miRNAs
miRNA expression profile
Expression profile of circulating miRNA correlated to osteoporosis
Time frame: Baseline, 2, 6 and 12 months of treatment
Bone Mineral Density
Bone Mineral Density (BMD), tested via a DEXA scan and expressed in T-score
Time frame: Baseline, 2, 6 and 12 months of treatment
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Aug 2029, 48 months after the start.
Of 220 non-industry interventional studies with no phase under Osteoporosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 49. This study's planned 48 months is above that.
Counting every sponsor, half of 239 studies reached it within 26 months; a quarter within 9 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →